{
    "clinical_study": {
        "@rank": "15138", 
        "arm_group": [
            {
                "arm_group_label": "Nintedanib (BIBF 1120) + BSC", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo + BSC", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients\n      with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard\n      chemotherapy and biological agents."
        }, 
        "brief_title": "Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Age >= 18 years\n\n          -  Signed informed consent\n\n          -  Histologically or cytologically confirmed colorectal adenocarcinoma\n\n          -  Metastatic or locally advanced disease not amenable to curative surgery and/or\n             radiotherapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status = 1\n\n          -  At least one measurable lesion according to Response Evaluation Criteria In Solid\n             Tumours (RECIST) version 1.1\n\n          -  Progression on standard therapies or withdrawn from standard treatment due to\n             unacceptable toxicity. Previous standard treatment must include all of the following:\n\n          -  - fluoropyrimidine\n\n          -  - oxaliplatin: Patients treated with oxalipatin in adjuvant setting should have\n             progressed within 6 months of completion of adjuvant therapy or they must have been\n             treated with oxaliplatin for metastatic disease\n\n          -  -  irinotecan\n\n          -  -  bevacizumab or aflibercept\n\n          -  - cetuximab or panitumumab for patients with K-Ras wt or Ras wt tumours\n\n          -  - previous treatment with regorafenib is allowed\n\n          -  - Life expectancy of at least 12 weeks\n\n          -  -  Hepatic function: aspartate aminotransferase (AST)/ Alanine Amino Tranferase (ALT)\n             = 1.5 X Upper Limit of Normal (ULN) and bilirubin = ULN for patients without liver\n             metastases. AST/ALT = 2.5 X ULN and bilirubin = ULN for patients with liver\n             metastases. Patients with Gilbert syndrome and bilirubin < 2 X ULN and normal AST/ALT\n             are eligible\n\n          -  Coagulation parameters: International normalised ratio (INR) < 2 and prothrombin Time\n             (PTT) = 2xULN\n\n        Exclusion criteria:\n\n          -  Previous treatment with nintedanib\n\n          -  toxicity attributed to previous anticancer therapy that did not resolve to Common\n             Terminology Criteria for Adverse Events (CTCAE)  grade =1\n\n          -  History of other malignancies in the last 5 years, in particular those that could\n             interfere with interpretation of results.\n\n          -  Serious concomitant disease or medical condition affecting compliance with trial\n             requirements or which are considered relevant for the evaluation of the efficacy or\n             safety of the trial drug,\n\n          -  Significant cardiovascular diseases\n\n          -  History of severe haemorrhagic or thromboembolic event in the past 12 months\n\n          -  Bleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or\n             similar agents requiring therapeutic INR monitoring\n\n          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of\n             study drug\n\n          -  Patient with brain metastases that are symptomatic and/or require therapy.\n\n          -  Patients of childbearing potential who are sexually active and unwilling to use a\n             highly effective method of contraception\n\n          -  Pregnancy or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "764", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149108", 
            "org_study_id": "1199.52", 
            "secondary_id": "2012-000095-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nintedanib (BIBF 1120) + BSC", 
                "intervention_name": "Nindetanib (BIBF 1120)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + BSC", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + BSC", 
                "intervention_name": "BSC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Nintedanib (BIBF 1120) + BSC", 
                "intervention_name": "BSC", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 26, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer Refractory to Standard Therapies.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Dept of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Canada: Health Canada", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Danish Medicines Agency", 
                "France: Agence Nationale s\u00e9curit\u00e9 m\u00e9dicament et des produits sant\u00e9", 
                "Germany:", 
                "Hong Kong:", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy:", 
                "Japan:", 
                "Korea: Ministry of Food and Drug Safety", 
                "Luxembourg:", 
                "Mexico:", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Poland: Registration Medicinal Product Medical Device Biocidal Product", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Spain: Spanish Agency of Medicines and Medical Devices", 
                "Sweden: Medical Products Agency", 
                "Taiwan : Food and Drug Administration", 
                "Turkey: Ministry of Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary endpoint is progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "22 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Key secondary endpoint is Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }, 
            {
                "measure": "Objective tumour response", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }, 
            {
                "measure": "Disease control", 
                "safety_issue": "No", 
                "time_frame": "22 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}